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A B S T R A C T
The loss of the corneal endothelial cells, especially in a first postoperative year, has been observed in patients who un-
derwent penetrating keratoplasty (PK). The implantation of new generation of »iris claw« phakic IOL (Verisyse) in re-
fractive cases has been shown to cause clinicaly insignificant endothelial cell loss. In our prospective case series we inves-
tigated the endothelial cell loss and clinical outcome in patients that either underwent PK and implantation of PCIOL or
PK and implantation of Verisyse IOL. In the first group of 9 patients scheduled for PK, implantation of Verisyse was per-
formed due to the absence of the posterior capsule support. 2 of these patients had angle supported ACIOL, 4 patients
were aphakic and 3 had posttraumatic cataract with ruptured posterior capsule. The second group of 12 patients had
standard »triple« procedure (PK + ECCE + PCIOL). BCVA of both groups of patients prior the operation was hand
movement in 12 patients, light perception in 7 patients and 0,05 in 3 patients. The preoperative endothelial cell count of
the donor grafts obtained from the eye bank was 2800 cells/mm2 on average. The follow up was 6–10 months. Six months
after the operation all »Verysise« patients maintained transparent graft. Postoperative visual acuity improvement was re-
corded in 18 out of 21 eyes (85,7 %). Best spectacle corrected visual acuity of 0,3 was achived in 55,5% in the Verisyse
group and in 50,0% of »triple procedure« group. The endothelial cell count and morphology were estimated on the specu-
lar microscope on a monthly basis. Mean endothelial cells loss in patients with PK and Verysise was 40± 8% and in pa-
tients with »triple« procedure was 42±12% at 10 postoperative months. There was no significant difference in the endo-
thelial cell loss and clinical outcome between the group of patients who had PK and Verysise as compared to those with
implanted PCIOL.
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Introduction
Combined penetrating keratoplasty and extracapsu-
lar cataract surgery with intraocular lens implantation
(»triple« procedure) has been performed with increasing
success for patients with corneal disease and cataract. It
has several advantages, such as single procedure, rapid
visual rehabilitation and no additional endothelial trau-
ma. However, open sky procedure may be accompanied
by uncontrollable vitreous pressure followed by posterior
capsule rupture and difficulty of IOL implantation, while
the worst complication may be expulsive hemorrhage1.
Posterior chamber intraocular lens (PCIOL) offers
several advantages and many authors recommend it even
in eyes lacking capsular or zonular support. Scleral fixa-
tion of PCIOL is a method to overcome lack of capsular
support but is technically more difficult, has high compli-
cation risk and is time-consuming compared to ACIOL im-
plantation. A recent study with long-term follow up has
shown that scleral-fixated PCIOLs may be associated with
high rates of postoperative complications and reopera-
tion1. If some remnants of capsular bag persist in some
cases IOL can be implanted in the posterior chamber on
these remnants, but if significant capsular support is lost
or extensive vitreous surgery is required, it is advisable
to fixate an IOL to the iris or to the sclera. Iris fixation is
preferable due to its rapidity, ease, reversibility and sa-
fety. Scleral fixation is used if there is inadequate iris to
provide support and an ACIOL is contraindicated.
The implantation of new generation of »iris claw«
Verisyse lenses has been shown to cause insignificant en-
dothelial cell loss in a refractive surgery cases. The de-
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vice is a single-piece, elliptical, polymethylmethacrylate
(PMMA) lens with a slight anterior vault. It is designed
for implantation into the anterior chamber of the phakic
and aphakic eye. Proper fixation requires about 1 mm of
iris tissue. An advantage of the lens is its ease of attach-
ment and detachment. It can be repositioned during sur-
gery or easily removed, if necessary. It is available in two
sizes, 6 mm and 5 mm, each with a different diopter
range. Because the lens attaches to a relatively immobile
part of the iris, the pupil can be dilated2–4. Verisyse
Aphakia IOL are lenses for primary or secondary implan-
tation after ICCE, ECCE and Phacoemulsification. Com-
plications such as iris chafing, pigment dispersion, pu-
pillary block and dislocation are rare with this technique.
The aim of this prospective study was to evaluate
postoperative results and the endothelial cell loss in the
patients that underwent penetrating keratoplasty (PK)
and implantation of »iris claw« Verisyse IOL as compared
to PK and implantation of PCIOL (standard »triple« pro-
cedure).
Materials and methods
We prospectively studied 21 patients undergoing pen-
etrating keratoplasty combined with either: a) Verisyse
IOL implantation (n=9) or b) posterior chamber IOL im-
plantation (n=12) between February 2009 and June
2009. In the first group of 9 patients scheduled for PK,
implantation of Verisyse Aphakia IOL (AMO, USA) was
performed due to the absence of posterior capsule sup-
port. Two of these patients had angle supported ACIOL,
4 patients were aphakic and 3 had posttraumatic cata-
ract without sufficient capsular support for PCIOL. The
second group of 12 patients had standard »triple proce-
dure« (PK+ ECCE+ PCIOL).
BCVA of patients prior to the operation was hand
movement in 12 patients, light perception in 7 patients
and 0.05 in 3 patients. The follow-up was 6–10 months.
All surgeries were done by the same surgeon (I.D.).
There were 7 women and 14 man. The mean age at the
time of penetrating keratoplasty was similar between
groups: 51 years in Verisyse group and 54 in »triple
group« (ranged from 10 to 80 years). Corneal patologies
included bullous keratopathy, preperforated corneal ul-
cer, corneal scar after perforative injury, corneal leuco-
ma, sy Steven-Johnson, rejected graft, keratoconus and
keratoglobus. Indications for penetrating keratoplasty in
our group of patients are shown in Table 1.
Preoperative evaluation
Preoperatively all patients underwent a complete ocu-
lar examination which included visual acuity assess-
ment, intraocular pressure measurement, slit lamp (CSO
Digital vision, Italy) and dilated fundus examination (if
possible), A and B-scan ultrasonic examination (Ultra-
scan Imaging System, Alcon, USA), anterior segment im-
aging (VisanteTM OCT, Carl Zeiss, Germany and Wave-
light Allegro Oculyzer, Germany). Intraocular lens (IOL)
power was calculated echographically, using the Sanders-
-Retzlaff-Kraff II (SRK-II) formula. If the fellow eye was
healthy and anamnestic data suggested similar prepa-
tology situation in both eyes IOL Master calculation
(IOL MASTER, Carl Zeiss Meditec AG, Germany) was
made for a fellow eye to double check IOL power that was
calculated echographically5.
Surgical technique
All penetrating keratoplasties were done by the same
experienced surgeon, under general anesthesia or with
parabulbar block with sedation. Standard PK surgical
technique was used throughout. The donor corneal but-
ton was trephined from the endothelial surface of the
corneoscleral button (Barron Vacuum Trephine, Katena
Product USA). The donor button was 0.5 mm larger in
diameter than the planned diameter of the host, to facili-
tate watertight closure, minimize postoperative flatten-
ing (to obtain deeper anterior chamber) and reduce pos-
sibility of postoperative glaucoma. The average donor
trephanation size range from 7.50–9.00 mm. The Ophtec
corneal trephane system was used for trephination of the
recipient cornea. The average recipient trephination size
range from 7.00–8.50 mm. In a »triple« cases the lens nu-
cleus was extracted and the cortical remants carefully as-
pirated (Infiniti, Alcon, USA), leaving behind an intact
posterior capsule. The PCIOL was than inserted. Visco-
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TABLE 1
INDICATIONS FOR PENETRATING KERATOPLASTY COMBINED WITH VERISYSE IOL IMPLANTATION OR WITH POSTERIOR CHAMBER
IOL IMPLANTATION (»TRIPLE«)
Corneal pathologies Number of eyes Percentage (%)










































elastic was used to separate the anterior and posterior
lens capsules to facilitate »in the bag loop« placement. In
a Verisyse group, ACIOL or cataract remnants were ex-
tracted, vitrectomy was performed until we had a »clear«
pupil zone, myostatic was applied and then Verisyse IOL
was attached to the iris. Peripheral iridectomy was per-
formed at the 12 o'clock meridian to prevent postopera-
tive IOP elevation.
Donor age ranged from 26 to 70 years with mean of 47
years. The preoperative endothelial cell count of the do-
nor graft which was obtained from the certified eye bank
was at least 2300 cells/mm2. Average Donor tissue char-
acteristics are shown in Table 2.
Postoperative care
Postoperatively, all patients recieved topical steroids,
antibiotics and artificial tears. If needed steroid and
cycloplegic combination was administered subconjucti-
vally. In a first postoperative week examinations were
made each day for first 7 days, then weekly for first
month and monthly thereafter. Postoperative examina-
tions consisted of visual acuity assesment, slit-lamp ex-
amination, intraocular pressure measurement, endothe-
lial cell count (Specular mycroscope CSO, Italy), anterior
segment imaging, fundus and ultrasonic examinations.
Statistical methods
Since we compared three different parameters before
and after surgery, we used student t-test with signifi-
cance value of 0.05.
Results
Patients in Verisyse group (Figure 1.) and 11 out of 12
in »triple« group maintained transparent graft. Postop-
erative BCVA in the group of patients with Verisyse IOL
(n=9) and »triple cases« (n=12) is presented in Table 3.
Postoperative visual acuity improvement was recorded in
18 out of 21 eyes (85,7%). Low BCVA<0.1 in both groups
was associated with accompanied eye diseases or earlier
eye surgeries causing retinal pathology (macular oedema
n=2) and postoperative IOP elevation (n=2). Best spec-
tacle corrected visual acuity of 0,3 was achived in 55,5 %
in the Verisyse group and in 50,0 % of »triple procedure«
group.
Elevated intraocular pressure (IOP) occured in 2 out
of 9 patients (22,2%) with Verisyse IOL, and in 1 of 12
(8%) patients with PCIOL. Those 3 patients had IOP>25
mm Hg occuring on a first postoperative day. In one pa-
tient from Verisyse group high IOP persisted beyond 20
days after surgery and was regulated by trabectulectomy.
After trabeculectomy IOP remained =14 mmHg for next
6 months. Second Verisyse patient and one »triple« case
with IOP >25 responeded well to topical anti glaucoma
drops and remained on topical treatment for following 4
months with IOP <16 mm Hg. Mean postoperative IOP
at the 6 months follow up for Verisyse group was 15,2±6
mm Hg and for »triple group« was 14,6±5 mm Hg
Of other postoperative complications epithelial defect
(ED) developed 14 days after surgery in 2 cases. Patients
were conservatively treated with subconjunctival ste-
roids, artificial tears and therapeutic soft contact lens.
Healing of the defect was obtained in both cases in 10
and 12 days.
Irregular pupil was seen in 2/9 (22,2%) of cases with
implanted Verisyse IOL without any subjective com-
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Fig. 1. Patient who had bullous keratopathy A. Preoperatively B.
After PK, explantation of ACIOL and implantation of Verisyse
IOL (jpg files).
Fig. 2. Visante OCT measurment of anterior chamber depth
after PK and Verisyse IOL implantation (jpg files).
plains from patients. Examination by slit-lam mycros-
copy did not show any damage to the iris tissue.
Endothelial cell density (ECD) was continously che-
cked up in both groups during the postoperative period
(Table 4). Our results show that the largest percentage of
cell loss is seen in first 5 months and remaines almost
stable up to 10 months postoperatively. We haven't seen
any significant difference in EC loss between Verisyse
and »tripple« group after 10 months of follow up.
Each patient from Verisyse group underwent anterior
segment OCT imaging to establish the distance between
Verisyse lens and corneal graft. This distance was higher
than 1 mm (peripherally) and higher than 1.5 mm (cen-
trally) in all cases (Figure 2).
Discussion
In all PK procedures and especially in combined pro-
cedures all attempts should be made to minimize endo-
thelial cell loss in the intraoperative and postoperative
period. Intraocular lens implantation is arguably the
most challenging step in this surgery6.
Aphakia is defined by the absence of the natural crys-
talline lens in the eye. It is encountered in patients who
undergone complicated surgery or trauma7,8. With the
advent of modern cataract surgery and better training of
cataract surgeons, aphakia has become less common over
the years. Verisyse Aphakia IOL are lenses for primary or
secondary implantation in aphakia. These intraocular
lenses are substantially different from all pupil-suppor-
ted lenses of the past. Verisyse IOL are peripheral »iris
bridge« supported lenses, and not »iris/pupil supported«
lenses as e.g. the Binkhorst lens or the Medallion lens of
the past which were supported by loops placed in contact
with the pupil border. IOL haptics (fixation arms) of this
lens are attached to the midpheripheral virtually immo-
bile iris stroma, thus allowing the pupil unrestricted abil-
ity to dilate and constrict. The two diametrically opposed
haptics ensure stable fixation to the iris, preventing
pseudo-phakodonesis and the risk of post-operative de-
centration. The vaulting of Verisyse IOL provides opti-
mum clearance between this ACIOL and the cornea as a
free flow of aqueous is ensured by the vaulted lens de-
sign. It is important though to perform an iridectomy
during the surgery to prevent elevation of IOP after
surgery7,9.
In eyes with insufficient or no capsular support, IOL
implantation can be made in several manners. Anterior
chamber or iris-fixated IOLs can be implanted, or, alter-
natively, a posterior chamber IOL can be fixated in the
ciliary sulcus using transscleral suturing. The safety and
long-term efficacy of a transsclerally sutured PCIOL are
less than satisfactory. The transsclerally sutured IOL is
associated with a steep learning curve and requires spe-
cial steps that anterior surgeon may not use routinely.
Transscleral suturing of an IOL has problems related to
accurate suturing at the ciliary sulcus and can be compli-
cated by intravitreal hemorrhage, retinal detachment,
lens subluxation, and suture erosion10–12. In PK surgery,
the conventional wisdom is to reduce the »open-sky« du-
ration to as short as possible as there is an associated risk
for expulsive hemmorage or choroidal effusion. IOL fixa-
tion to the iris reduce the chance of these dangerous
events. Iris suturing may be technically difficult in
aphakia cases and may cause iris haemorrhage. As the
open-sky procedure in aphakia is often associated with
anterior vitrectomy, the resultant hypotony makes su-
ture placement and adjustment difficult. New generation
of aphakia lenses such as Verisyse are simple to use in
»open-sky« cases and shorten the surgery time signifi-
cantly as comparing to scelar fixation or suturing of IOL.
One of the complications that has been associated with
iris-fixated IOLs is postoperative cell loss via potential
mechanical contact between the IOL and corneal endo-
thelium. In preliminary Scheimpflug biometry study, the
distance between the Artiflex lens and the endothelium
was determined to be well above the 1,00 mm centrally
and peripherally. Another Scheimpflug study with 12
months of follow up confirmed sufficent distance be-
tween surrounding tissues and showed stability of the
results13,14. In our study, we have demonstrated with
I. Dekaris et al.: Verisyse Lens and Corneal Graft, Coll. Antropol. 34 (2010) Suppl. 2: 73–77
76
TABLE 4




Mean postoperative cell loss (%)
1 month 5 month 10 month
Verisyse IOL (n=9) 2709±180 20.8±10 40.5±14 42±12
Triple procedure (n=12) 2905±210 15±11 38.3±12 40±8
TABLE 3
COMPARISON OF 10 MONTH BCVA IN THE GROUP OF PATIENTS WITH CORNEAL GRAFT AND VERISYSE OR PCIOL (»TRIPLE«)
















OCT measurments that there is no touch between the
Verisyse IOL and endothelium and that there is no sig-
nificant difference in postoperative endothelial cell loss
between patients that underwent »triple« procedure and
patients with Verisyse IOL.
Conclusion
According to our results, although in a small sample,
Verisyse lens is safe and efficacious method to correct
aphakia when combined with penetrating keratoplasty.
No significant difference in graft survival rate, BCVA
and postoperative endothelial cell density was found be-
tween Verisyse patients and those who underwent stan-
dard »triple« procedure.
Abbreviations: PK – Penetrating keratoplasty, IOL –
Intraocular lens, ACIOL – anterior chamber intraocular
lens, »Triple procedure« – penetrating keratoplasty +
cataract extraction + posterior chamber intraocular lens,
BCVA- best corrected visual acuity
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PENETRANTNA KERATOPLASTIKA KOMBINIRANA SA VERISYSE IRIS FIKSACIJSKOM LE]OM
– KOLIKO JE SIGURNA ZA PRESADAK?
S A @ E T A K
Gubitak endotelnih stanica donorske ro`nice je znana pojava nakon transplantacije ro`nice. Ugradnja najnovijih
modela »iris –fiksacijskih« le}a (Verisyse) u refraktivnoj kirurgiji ukazuje na klini~ki neznatan gubitak endotelnih sta-
nica. U na{oj prospektivnoj studiji promatrali smo klini~ki u~inak i gubitak endotelnih stanica u pacijenata koji su bili
podvrgnuti transplantaciji ro`nice u kombinaciji sa: a) ugradnjom iris-fiksacijske i b) implantacijom le}e u stra`nju
kapsulu. U prvoj grupi od 9 pacijenata ugra|ena je Verisyse afaki~na intraokularna le}a (IOL) zbog nedostatka stra`nje
kapsule i nemogu}nosti implantacije IOL-a u stra`nju sobicu. Dva pacijenta iz ove grupe imali su »angle supported«
IOL u prednoj o~noj sobici, ~etiri pacijenta su bila afaki~na a tri su imala posttraumatsku kataraktu sa puknutom
stra`njom kapsulom. Drugoj grupi od 12 pacijenata u~injena je standardna »triple« operacija (KPP + ECCE+ PCIOL).
Vidna o{trina prije operacije je bila mahanje rukom pred o~ima u 12 pacijenata, svjetlost projekcija u 7 pacijenata i 0,05
u 3 pacijenta. Preoperativni broj endotelnih stanica donorskoh ro`nica bio je u prosjeku 2800 stanica/mm2. Postope-
rativni period pra}enja bio je 6–10 mjeseci. [est mjeseci nakon operacije, svi pacijenti sa Verisyse IOL imali su bistar
transplantat. Postoperativno pobolj{anje vidne o{trine je zabilje`eno u 18 od 21 operirana oka (85,7%). Vidna o{trina
0.3 je postignuta kod 55% pacijenata u Verisyse grupi te u 50% u »triple« grupi. Broj i morfologija endotelnih stanica
pra}ena je spekularnim mikroskopom svaki mjesec postoperativno. Gubitak endotelnih stanica do 10-og postoperativ-
nog mjeseca u Verisyse grupi bio je 42±12% te 40±8% u »triple« grupi. U na{oj studiji nije uo~ena statisti~ki zna~ajna
razlika u postoperativnom gubitku endotelnih stanica izme|u grupe pacijenata sa KPP-om i ugradnjom Verisyse le}e i
grupe pacijenata sa KPP-om i ugradnjom le}e u stra`nju sobicu.
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